Page 2 - Leopold Bertea News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Leopold bertea. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Leopold Bertea Today - Breaking & Trending Today

Immunicum AB: Immunicum AB (publ) Interim Report January

JANUARY - MARCH IN SUMMARY Net sales for the period amounted to KSEK 1,794 (-).Result for the period amounted to KSEK -27,582 (-41,571).Earnings and diluted earnings per share totaled SEK -0.14 (-0.25).Immunicum ....

Vastra Gotalands Lan , Julie Seidel , Mario Brkulj , Erik Manting , Leopold Bertea , Technology Officer , Valency Communications , Dutch National Growth Fund , Acute Myeloid , Chief Technology ,

Immunicum AB: Immunicum Appoints Leopold Bertea as Chief Technology Officer

Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced the appointment of Leopold Bertea ....

France General , Julie Seidel , Mario Brkulj , Erik Manting , Leopold Bertea , Les Ulis , Member Of The Cellectis Executive Committee , Valency Communications , Chief Technology Officer , Senior Vice President Technical Operations Europe , Cellectis Executive , General Manager , Site Head , Chemical Engineering , Chief Executive Officer ,

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
March 04, 2021 16:42 ET
| Source:
Cellectis Inc.
Cellectis Inc.
New York, New York, UNITED STATES
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers
Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting
Partner Allogene Therapeutics presented initial results from Phase 1 ALPHA clinical study of licensed ALLO-501 in r/r NHL at 2020 ASCO Annual Meeting and from Phase 1 UNIVERSAL clinical study of licensed ALLO-715 in r/r MM at 2020 ASH Annual Meeting ....

United States , New York , France General , North Carolina , Stanford University , Stephan Grupp , Laurent Poirot , Philippe Duchateau , Cytovia Theraputics , Kyung Nam Wortman , Steve Doares , Iovance Biotherapeutics , Simon Harnest , Mark Frattini , Leopold Bertea , Iovance Biotherapeutic , Carrie Brownstein , Jean Pierre Garnier , Margaret Gandolfo , Conor Mcgoldrick , Head Of Information Technology , Calyxt Inc , American Society Of Clinical Oncology , Clinical Development Appointments , Louis Pasteur University Of Strasbourg , Delta Consulting Group ,